Clinical evidence
Sacral neuromodulation compared to medications
For the InterStim™ systems for overactive bladder
Sacral neuromodulation (SNM) delivered by the InterStim™ system outperforms medications,† as shown in a six-month randomized study comparing SNM to standard medical therapy (SMT) in patients with symptoms with OAB.1
Numbers reflect as treated results, defined as subjects with diary data at baseline and six months (p=0.002). Intent-to-treat results, which include all randomized subjects, are 61% for SNM and 42% for SMT (p=0.02).
Device-related adverse events occurred in 31% of SNM patients, and medication-related adverse events occurred in 27% of SMT patients. No unanticipated adverse events were reported. No serious device- or medication-related adverse events were reported. The most common device-related AEs were undesirable change in stimulation, implant site pain, and implant site infection.
◼ SNM◼ SMT
Device-related adverse events occurred in 31% of SNM patients, and medication-related adverse events occurred in 27% of SMT patients. No unanticipated adverse events were reported in SNM patients. No serious device- or medication-related adverse events (AE) were reported. The most common device-related AEs were undesirable change in stimulation, implant site pain, and implant site infection.
◼ SNM◼ SMT
Take convenient courses specifically designed for clinicians treating patients with OAB, non-obstructive urinary retention, and chronic fecal incontinence (FI).
InterStim™ may offer your patients relief from bladder and bowel symptoms.
† Anticholinergic/antimuscarinic.
‡ Numbers reflect as treated results, defined as subjects with diary data at baseline and six months (p=0.002). Intent to treat results, which include all randomized subjects, are 61% for SNM and 42% for SMT (p=0.02).
§ Based on OABqol-HRQL, Minimally Important Difference (MID) = 10 points.